PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS Russian patent published in 2017 - IPC C07D487/04 A61K31/519 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula (II) or (II') or pharmaceutically acceptable salts thereof. Compounds inhibit activity of protein kinase CK2 (casein kinase II) or PIM kinase and can be used for treating proliferative diseases selected from cancer of various cell lines, such as breast cancer, lung, skin cancer etc, angiogenesis, as well as other kinase related conditions, including inflammation, vascular diseases, pathogenic infections, neurodegenerative diseases, some immunological diseases. In compounds of formula (II) or (II')

or

Z³ denotes N and Z⁴ denotes CR⁵; or Z³ denotes CR⁵ and Z⁴ denotes N; or Z³ and Z⁴ both denote N; each R⁵ is independently selected from halo, -CN and -R, where each R is independently selected from H and optionally substituted C1-C4 alkyl; each R², R³ and R⁴ is independently selected from H and optionally substituted C1-C10 alkyl; X denotes S or NR²; Y is O or S; Z is O or S; L is a bond, -CR⁷=CR⁸-, -C≡C- or -(CR⁷R⁸)_m-, and W is optionally substituted C1-C10alkyl, optionally substituted with 1-10-member heteroalkyl, optionally substituted C6-C12aryl, Optionally substituted 5-12-member heteroaryl, -NR⁷R⁸, -OR⁷, -S(O)_nR⁷, -CONR⁷R⁸, optionally substituted 3-10-member heterocyclyl, optionally substituted with C3-C10carbocyclyl, optionally substituted C2-C10alkenyl, optionally substituted C2-C10alkynyl or -CR⁷R⁸R⁹; or L is a bond, -NR⁷-, -O-, -S(O)_n-, -(CR⁷R⁸)_m- or -(CR⁷R⁸)_m-NR⁷-; and W is selected from optionally substituted C6-C12aryl, optionally substituted 5-12-member heteroaryl and -NR⁷R⁸; where each R⁷ and R⁸ and R⁹ is independently selected from H, optionally substituted C1-C10alkyl, optionally substituted 1-10-member heteroalkyl, optionally substituted C3-C10carbocyclyl, optionally substituted 3-10-member heterocyclyl, optionally substituted C3-C10carbocyclylalkyl, optionally substituted 3-10-member heterocyclylC1-C8-alkyl, optionally substituted C6-C12aryl, optionally substituted C7-C12arylalkyl, optionally substituted 5-12-member heteroaryl and optionally substituted 5-12-member heteroarylC1-C8alkyl; or R⁸ and R⁹, taken together with carbon atom to which they are bonded form =O(oxo); or R⁷ and R⁸, taken together and arranged on one carbon atom or on adjacent bonded atoms (CR⁷R⁸)_m, either alone, or as part of another group, form a 3-8-member carbocyclic ring or a heterocyclic ring; or R⁷ and R⁸, taken together with a nitrogen atom to which they are bonded, form an optionally substituted 5-10-member heterocyclic or heteroaryl ring, which optionally contains one or more additional ring heteroatoms selected from N, O and S; provided that no more than one group from R⁷ and R⁸ in -NR⁷R⁸ is selected from a group consisting of alkoxy, alkylamino, dialkylamino and heterocyclyl; each n is independently equal to 0, 1 or 2; each m is independently equal to 1, 2, 3 or 4; and R^1A is selected from H, optionally substituted C1-C10alkyl; and R^1B each is independently selected from H, optionally substituted C1-C10alkyl, optionally substituted 3-10-member heterocyclyl, optionally substituted C3-C10carbocyclyl, optionally substituted C3-C10carbocyclylalkyl, optionally substituted 3-10-member heterocyclyl-C1-C8alkyl, optionally substituted C6-C12aryl, optionally substituted C7-C12arylalkyl, optionally substituted 5-12-member heteroaryl or optionally substituted 5-12-member heteroaryl-C1-C8alkyl.

EFFECT: substitutes for saturated and unsaturated carbon atoms are selected from corresponding groups specified in patent claim.

58 cl, 14 dwg, 113 tbl, 299 ex